Abstract:Background The primary objectives of the treatment for the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are to produce rapid, sustained, and safe improvements in the symptoms that affect the quality of life in the majority of men over 50. In this study, we evaluated the efficacy and safety of the combined therapy with terazosin (alpha 1-adrenergic receptor antagonist) and tolterodine (anticholinergic agent) for LUTS associated with BPH. Methods This combination study included 69 patients diagnosed with LUTS associated with BPH based on the International Prostate Symptom Scores (IPSS), urinary flow rate, prostate volume, urinary residual, and their serum prostate-specific antigen levels. Initially, 191 patients were treated with terazosin 2 mg once daily for one week. Those patients with continued LUTS after the initial treatment were allocated randomly into two groups: terazosin group (n=36) in which patients were treated with terazosin 2 mg once daily for six weeks, and combination group (n=33) in which patients were treated with both terazosin 2 mg once daily and tolterodine 2 mg twice daily for 6 weeks. Results The IPSS were significantly improved in both groups after treatment, and the reduction of IPSS in the combination group was significantly greater than that in the terazosin group (P < 0.01). A decrease in urgency, frequency and nocturia were the main contributory factors causing the reduction of IPSS in the combination group. The differences about the peak urinary flow rate and the residual urine from the baseline values were noted in both groups after treatment, but were not significant between the two groups. The incidence of adverse effects in the combination group was higher than that in the terazosin group. As expected the most common adverse effect was mouth dryness which was associated with anticholinergic drugs such as tolterodine. Conclusions Patients with LUTS associated BPH appear the improved IPSS after combined therapy with terazosin and tolterodine. This study, although short term and limited numbers of patients, provides evidence that the combined therapy with terazosin plus tolterodine is a good approach for meeting the objectives of rapid, sustained, and safe improvements in the LUTS associated with BPH. And the profile of patients in this study might be used as the indication of such combined therapy for LUTS associated with BPH without urodynamic evaluation.

Terazosin treatment in BPH/LUTS: a prospective, randomized, multicenter study

A multicenter prospective clinical study on the effectiveness and safety of terazosin in the treatment of Chinese benign prostatic hyperplasia patients

Efficacy and Safety of Combined Therapy with Terazosin and Tolteradine for Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: a Prospective Study

Efficacy of Terazosin Therapy for Mild Hypertension Patients with Lower Urinary Tract Symptoms

Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review.

Tamsulosin Versus Terazosin for Benign Prostatic Hyperplasia: A Systematic Review

Efficacy Of Combined Amlodipine/Terazosin Therapy In Male Hypertensive Patients With Lower Urinary Tract Symptoms: A Randomized, Double-Blind Clinical Trial

Clinical Comparison of Selective and Non-Selective Alpha 1A-Adrenoceptor Antagonists for Bladder Outlet Obstruction Associated with Benign Prostatic Hyperplasia: Studies on Tamsulosin and Terazosin in Chinese Patients. the Chinese Tamsulosin Study Group.

Personalized Therapeutics of Α1-Blockers In patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Efficacy and Safety of Long-Term Administration of Tamsulosin Hydrochloride in Patients with LUTS Suggestive of BPH

Combination of Tamsulosin and Tolterodine Alleviates Refractory Lower Urinary Tract Symptoms in Male Patients

Evaluation of the Effectiveness of Terazosin, Tamsulosin a nd Finasteride for Benign Prostatic Hyperplasia

Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia

Single drug versus combination therapy with terazosin and amlodipine for middle-aged and old male patients with bladder outlet obstruction associated with benign prostatic hyperplasia and their quality of life

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Tamsulosin Plus Tadalafil Compared With Tamsulosin Alone in Treating Males With Lower Urinary Tract Symptoms Secondary to Benign Prostrate Hyperplasia

Effect of Doxazosin Gastrointestinal Therapeutic System 4 Mg Vs Tamsulosin 0.2 Mg on Nocturia in Chinese Men with Lower Urinary Tract Symptoms: a Prospective, Multicenter, Randomized, Open, Parallel Study.

A Comparative Study on the Safety and Efficacy of Tamsulosin and Alfuzosin in the Management of Symptomatic Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Trial

Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study

The comparison between finasteride and tamsulosin therapeutic efficacy in the treatment of symptomatic benign prostate hyperplasia

Silodosin is Effective for Treatment of LUTS in Men with BPH: a Systematic Review

Clinical efficacy of a short-term regimen of cardura XL on lower urinary tract symptoms and international prognostic scoring system in the treatment of benign prostatic hyperplasia